Explore

Trendline Trendline
Biotech IPOs Resurge in 2026, Tracking Performance of New Market Entrants

Biotech IPOs Resurge in 2026, Tracking Performance of New Market Entrants

Biotech IPOs Resurge in 2026, Tracking Performance of New Market Entrants
Trendline Trendline
Insmed's PAH Drug Shows Long-Term Efficacy, Projected to Reach $6 Billion in Sales

Insmed's PAH Drug Shows Long-Term Efficacy, Projected to Reach $6 Billion in Sales

Insmed's PAH Drug Shows Long-Term Efficacy, Projected to Reach $6 Billion in Sales
Trendline Trendline
Pfizer Faces Challenges in Maintaining Dividend Amid Patent Expirations

Pfizer Faces Challenges in Maintaining Dividend Amid Patent Expirations

Pfizer Faces Challenges in Maintaining Dividend Amid Patent Expirations
Trendline Trendline
Sellas Life Sciences Sees Stock Surge Amid Anticipation of Key Clinical Trial Results

Sellas Life Sciences Sees Stock Surge Amid Anticipation of Key Clinical Trial Results

Sellas Life Sciences Sees Stock Surge Amid Anticipation of Key Clinical Trial Results
Trendline Trendline
BeOne Medicines to Announce Second Quarter 2026 Financial Results Impacting Oncology Sector

BeOne Medicines to Announce Second Quarter 2026 Financial Results Impacting Oncology Sector

BeOne Medicines to Announce Second Quarter 2026 Financial Results Impacting Oncology Sector
Trendline Trendline
Scotiabank Projects Hecla Mining's FY2026 Earnings Amid Analyst Ratings

Scotiabank Projects Hecla Mining's FY2026 Earnings Amid Analyst Ratings

Scotiabank Projects Hecla Mining's FY2026 Earnings Amid Analyst Ratings
Trendline Trendline
Zoetis Inc. Faces Class Action Lawsuit Over Securities Violations

Zoetis Inc. Faces Class Action Lawsuit Over Securities Violations

Zoetis Inc. Faces Class Action Lawsuit Over Securities Violations
Reuters Reuters
Novartis faces drug pipeline test with valuation premium in focus

Novartis faces drug pipeline test with valuation premium in focus

By Bhanvi Satija LONDON, July 20 (Reuters) - Novartis investors will look beyond Tuesday's quarterly results for indications about three major drug trial readouts due in the second half of the year seen as vital to justifying the Swiss drugmaker's premium valuation.
Trendline Trendline
Principal Financial Group Increases Stake in Hecla Mining Company, Boosting Holdings to $38.85 Million

Principal Financial Group Increases Stake in Hecla Mining Company, Boosting Holdings to $38.85 Million

Principal Financial Group Increases Stake in Hecla Mining Company, Boosting Holdings to $38.85 Million
Trendline Trendline
Newmont Stock Highlights Large Cap Value Picks Amid Inflation Concerns

Newmont Stock Highlights Large Cap Value Picks Amid Inflation Concerns

Newmont Stock Highlights Large Cap Value Picks Amid Inflation Concerns
Trendline Trendline
Autoliv Reports Q2 Earnings Surpassing Estimates Amid Asia Growth and Cost Savings

Autoliv Reports Q2 Earnings Surpassing Estimates Amid Asia Growth and Cost Savings

Autoliv Reports Q2 Earnings Surpassing Estimates Amid Asia Growth and Cost Savings
Trendline Trendline
Autoliv's Q2 Earnings Surpass Expectations Due to Asia Growth and Cost Savings

Autoliv's Q2 Earnings Surpass Expectations Due to Asia Growth and Cost Savings

Autoliv's Q2 Earnings Surpass Expectations Due to Asia Growth and Cost Savings